Last reviewed · How we verify
Amoxicillin-Clarithromycin-Lansoprazole
This triple-therapy combination eradicates Helicobacter pylori by combining two antibiotics that inhibit bacterial protein synthesis with a proton pump inhibitor that reduces gastric acid.
This triple-therapy combination eradicates Helicobacter pylori by combining two antibiotics that inhibit bacterial protein synthesis with a proton pump inhibitor that reduces gastric acid. Used for Helicobacter pylori infection in peptic ulcer disease, H. pylori-associated gastritis.
At a glance
| Generic name | Amoxicillin-Clarithromycin-Lansoprazole |
|---|---|
| Sponsor | Fatma Zehra Arvas |
| Drug class | Triple therapy antibiotic combination with proton pump inhibitor |
| Target | Helicobacter pylori bacterial ribosomes (amoxicillin and clarithromycin); H+/K+-ATPase (lansoprazole) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin and clarithromycin are macrolide and beta-lactam antibiotics that disrupt bacterial protein synthesis and cell wall integrity, respectively. Lansoprazole suppresses gastric acid production, creating an optimal environment for antibiotic efficacy and allowing ulcer healing. Together, this regimen achieves high eradication rates of H. pylori infection.
Approved indications
- Helicobacter pylori infection in peptic ulcer disease
- H. pylori-associated gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Taste disturbance
- Headache
- Rash
Key clinical trials
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile (NA)
- The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection (PHASE3)
- Helicobacter Pylori Eradication Study (PHASE4)
- Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin (PHASE2)
- Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication (PHASE3)
- Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy (PHASE4)
- Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxicillin-Clarithromycin-Lansoprazole CI brief — competitive landscape report
- Amoxicillin-Clarithromycin-Lansoprazole updates RSS · CI watch RSS
- Fatma Zehra Arvas portfolio CI